Recombinant Human CLEC4C protein (rFc Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg2569

---

Validation Data Gallery

• 

  Purity of Recombinant Human CLEC4C was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human CLEC4C protein Asn45-Ile213 (Accession# Q8WTT0-1) with a rabbit IgG Fc tag at the N-terminus.
• GeneID: 170482
• Accession: Q8WTT0-1
• PredictedSize: 47.1 kDa
• SDS-PAGE: 50-65 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

CLEC4C (C-type lectin domain family 4 member C), also known as DLEC, BDCA-2, CD303, and HECL, is a type II membrane protein that contains C-type lectin domain. The C-type lectin domain family members share a common protein fold and have diverse functions, such as cell adhesion, cell-cell signaling, glycoprotein turnover, and roles in inflammation and immune response. CLEC4C is a specific surface marker of human plasmacytoid dendritic cells, centrally involved in antigen presentation and immune tolerance.

References:

1.Kanazawa N, et al. (2004) Immunobiology. 209(1-2):179-90. 
2.McGreal EP, et al. (2004) Mol Immunol. 41(11):1109-21.
3. Wilson NR, et al. (2022) Leuk Lymphoma. 63(1):19-30.
4.Boiocchi L, et al. (2013) Blood. 11;122(2):296-7.